Company news
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) news
Taysha Gene Therapies, Inc. news releases on 6ix. Latest, Oct 5, 2026: Taysha Gene Therapies Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
Press releases & updates
Taysha Gene Therapies Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
October 5, 2026
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
October 1, 2026
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
September 30, 2026
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
August 4, 2026
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
August 3, 2026
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
June 25, 2026
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
June 21, 2026
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 5, 2026
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
April 29, 2026
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
April 27, 2026
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
March 18, 2026
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
March 11, 2026
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
January 5, 2026
Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 3, 2025
Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4
October 27, 2025
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
October 15, 2025
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting
October 8, 2025
Taysha Gene Therapies Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
October 6, 2025
Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome
October 1, 2025
Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 11, 2025
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12
August 5, 2025
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
June 2, 2025
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
May 27, 2025
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
May 27, 2025
Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102
May 27, 2025
Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15
May 7, 2025
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update
February 25, 2025
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26
February 18, 2025
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13
November 5, 2024
Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
October 21, 2024
Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress
September 25, 2024
Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 11, 2024
Taysha Gene Therapies to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 12
August 4, 2024
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 4, 2024
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 4, 2024
Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome
June 17, 2024
Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting
June 11, 2024
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024
Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14
May 6, 2024
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
May 1, 2024
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
March 18, 2024
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
March 13, 2024
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome
February 28, 2024
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
February 14, 2024
Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference
January 21, 2024
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
January 9, 2024
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 4, 2024